



# shaping the future

5 EMERGING TECHNOLOGIES TRANSFORMING THE WORLD

# > Five emerging technologies

O1 O2 O3 O4 O5

QUANTUM COMPUTING

O2 O3 O4 O5

ARTIFICIAL INTELLIGENCE

BLOCKCHAIN

CYBER SECURITY



# **Quantum Computing: Overview**



#### **QUANTUM COMPUTING** WHAT IS IT?

Computers using quantum mechanical phenomena (superposition and entanglement) to exponentially increase compute power and tackle complex problems far beyond the physical limits of today's best supercomputers.

#### STATE OF PLAY

**Hardware:** multiple hardware approaches racing to become market standard. Google and IBM leading the pack. Rigetti, Honeywell, Intel, IonQ and QCI following close behind.
















**Software:** multiple players starting to proliferate, largely focused on translating traditional software approaches into code that can exploit quantum computers' capabilities.











# Quantum Computing: Use Cases

### <drug discovery>

2 **IDENTIFYING** MOLECULE **DISEASE DRIVERS SELECTION** Better algos and higher Ability to rapidly screen compute power to find massive virtual libraries of signals in large data potential molecules Ability to simulate and Improved modelling predict drug/patient accuracy enables significantly improved interactions could reduce failure rates and drug design time CLINICAL MOLECULE TRIALS **OPTIMIZATION** 

### <financial markets>

RISK MANAGEMENT

Algorithms for processing high volume high velocity data to optimize pricing decisions in market making

MARKET MAKING

TRADING **OPTIMIZATION** 

Better algos processing high volume high velocity data enables realtime rebalancing for better returns

**EXOTIC INSURANCE** PRICING

# <advanced manufacturing>

**MATERIALS SCIENCE** 

Simulating complex new molecules could create new materials with improved strength: weight ratios or energy-efficient production, etc) 

Accelerate decision making to enable improved control of realtime, complex supply chains

SUPPLY CHAIN **OPTIMIZATION**  **PRODUCT** DESIGN

Higher compute power to simulate component interactions in complex systems, enabling more precise product design

Ability to simulate exponentially more variables in production processes result in improved controls and yields

**PRODUCTION** 

CONTROL





# Internet of Things



# INTERNET OF THINGS WHAT IS IT?

A network of web-enabled sensors, computing devices, and machines capable of directly communicating with each other, either to share data or act on information received from one another

#### STATE OF PLAY



Hardware and infrastructure are well developed, though with room for improvement. Multiple competing technical standards lead to lack of interoperability between multiple ecosystems.



Abundant initial applications already live in the market, across consumer, medical, insurance, manufacturing, agriculture, smart city infrastructure, and energy (among others.)

Emerging fields include combining IoT with Al to drive autonomous IoT e.g. autonomous vehicles

#### **ENDGAME**



**Data Tsunami**: Internet-connected sensors embedded across a wide range of objects generates a deluge of data



"Smart Everything": embedded AI to drive autonomous decision making: e.g. smart roads, autonomous vehicles



The Edge: edge computing (and 5G) become enabling technologies that allow ever more complex decision making to be performed locally



# Internet of Things: Use Cases

### <medtech>

#### PREDICTIVE HEALTH **MONITORS**

Smart sensors combined with Al can give early warning of when wearers may suffer adverse events e.g. heart attacks, COPD

**Enables historically** institutionalized patients to be cared for at home e.g. elderly, cognitively challenged

**SMART HOMES FOR IN-PLACE CARE** 

#### **MEDICAL DIAGNOSTICS**

2

Ability to gather realtime data about the patient at the point of care enables faster diagnostics and personalized care

Allowing new forms of diagnostics and patient health monitoring

> **INGESTIBLE** SENSORS

### <new types of insurance>

#### **AUTONOMOUS VEHICLES INSURANCE**

Wearables enable improved digital therapeutics for managing chronic conditions, making it affordable for insurers to offer policies e.g. diabetes insurance

**CHRONIC CONDITION INSURANCE** 

**INSURANCE** 

**CLIMATE / CROP** 

Sensors deployed in agriculture, solar farms, wind farms etc enable dynamic, accurate pricing of climate risk

**SUPPLY CHAIN** INSURANCE

## <agritech>

#### **PRECISION CROP MANAGEMENT**

Sensors measuring mineral content, temperature, rainfall, wind and humidity trigger automatic actions (e.g. fertilisation or watering to maximize crop yields

Generate data to enable improved realtime control of cold chains, and automate decision making to reduce food waste

SUPPLY CHAIN **OPTIMIZATION** 

**GREENHOUSE AUTOMATION** 

Enables remote monitoring and control of greenhouse environments e.g. urban vertical farms

Realtime data generated by smart sensors allows for prediction of crop yields, optimal harvest time, risk of diseases and infestations, etc

> **PREDICTIVE ANALYTICS**



# > Cyber Security: Overview



The protection of computer systems and networks from theft or damage to their hardware, software or electronic data. Economies that increasingly exist in cyberspace will become increasingly vulnerable to cyber attacks and threats, and security teams risk being overwhelmed.

#### STATE OF PLAY

**Today:** Traditional antivirus products have given way to Al-driven behavioural analysis, network monitoring, and endpoint detection and remediation (EDR) solutions. Key players include:



CROWDSTRIKE Carbon Black. cybereason\*







Coming up: A shift toward XDR (extended detection and remediation across platforms) and autonomous cyber defense, capable of judgement to risk assess a threat and deliver a response. Requires proprietary artificial intelligence and deep learning models that are capable of making intuitive leaps on thin data



#### **ENDGAME**



Increasingly sophisticated solutions straddle multiple platforms (endpoints, email, servers, clouds, networks) to provide full cyber defensibility, matched by increasingly sophisticated bad actors deploying new and ingenious cyber attacks.



Proliferation of cyber threats leads to heavier reliance on machine intelligence to deploy automated defences, leaving human involvement to a decreasing percentage of instances.



Longer term, information security will be supplemented by quantum computing technologies to create quantum-proof unbreakable encryption protocols



# > Cyber Security: Use Cases

Software famously ate the world, and cyber attacks threaten every aspect of the world that is encoded in software. Thus cyber security touches almost every aspect of modern life. Instead of highlighting specific use cases of the technology, below we look at some ways in which autonomous cybersecurity will interact with the other emerging technologies that we highlight in this document.



### **IOT / Medical Devices / Agritech / Advanced Manufacturing**

Connected devices and wearable health trackers contain valuable data targeted by hackers

### **Digital Identities / Blockchain**

Theoretically secure, blockchain protocols have already proven to be vulnerable to hacks. If digital identities become the portal into formal economic and societal services, they become valuable targets for hackers to exploit

### **Data Troves / Artificial Intelligence**

Need to defend data troves acccumulated by the rise of telehealth, electronic health records, embedded finance and embedded insurance

### **Quantum-Ready defense**

Current encryption protocols on the Internet will be easily broken by quantum computers; cybersecurity needs to be ready for the quantum age



# > Artificial Intelligence: Overview



#### ARTIFICIAL INTELLIGENCE

than a human can. Caveat the Al **Effect**, where as soon as Al

#### STATE OF PLAY

**Hardware:** Multiple tech giants and well-funded startups developing next-gen Al chips, available via cloud or in devices. Capital-intensive endeavour but could unlock fields with huge potential e.g. AR/VR, IoT (edge devices).

#### **Tech Giants**











#### **Startups**

GRAPHCORE MYTHIC





**Software and Applications:** Widely integrated into applications across all sectors and use cases. Proliferation of open-source machine learning models and commodified AI capabilities.

#### WHERE ARE THE HARD PROBLEMS IN AI NOW?



#### **DEEP REASONING**

Expand beyond what deep learning does in image classification and perception into ability to reason



#### SMALL DATA DEEP LEARNING

Researchers pushing to figure out ways to train systems on less data for more complex and diverse tasks



# > Artificial Intelligence: Use Cases

### <medtech/pharma>

DRUG **DEVELOPMENT** 

Rapidly screen likely molecule candidates for certain diseases; especially powerful if coupled with quantum, computing

Microsurgeries where human movements are translated to more precise, minute actions with robotic assistance

PRECISION SURGERY / **ROBOTICS** 

**PREDICTIVE DIAGNOSTICS** 

Embedded Al in wearable medical devices can help identify patients at risk of adverse events e.g. heart attacks, COPD, etc

Increase diagnostic accuracy from lower cost devices, portable devices or lower resolution imaging modalities (e.g. ultrasound replacing MRI)

> **HARDWARE OPTIMIZATION**

<financial services>

THIN FILE CREDIT UNDERWRITING

Automate claims processing with detection of fraudulent claims via deepfaked proofs of identity, images or video

**INSURANCE CLAIMS PROCESSING** 

**PAYMENTS FRAUD** DETECTION

Algorithms to detect and block a wide range of fraudulent transactions

CREDIT MANAGEMENT / COLLECTIONS <advanced manufacturing>

**QUALITY CONTROL** 

Ability to spot subtle manufacturing defects in components can prevent more expensive or systemic problems down the line

Predict market demand for product updates and manufacturing volumes

**SUPPLY CHAIN OPTIMIZATION** 

**PREDICTIVE MAINTENANCE** 

Predicting when machines or products will malfunction can save huge costs in inspection or plant downtime

Algorithms to maximize throughput or to improve yields through improved manufacturing processes or product design

> **PRODUCT OR PROCESS DESIGN**



### > Blockchain



# BLOCKCHAIN WHAT IS IT?


A electronic **shared ledger** among disparate users to create an **immutable record** of transactions, updated by **consensus**, each **time-stamped** and linked to the previous one. Every time a set of transactions is added, that data becomes another block in the chain.

#### STATE OF PLAY

**Today:** Parallel developments in Blockchain technology in private-permissioned chains vs public-decentralised chains

#### **Ongoing Innovations:**

- 1) **Secondary Chains/ Side Chains –** off-loading transactions to a secondary network to increase transaction speeds
- 2) **Sharding** Splitting up transactions to be verified by separate parts of the network to increase transaction speeds
- 3) Developing **new consensus mechanisms** Consensus mechanisms (Proof of Work vs Proof of Stake) to improve energy efficiency
- 4) Improving algorithms to allow for more **complex code operations** on the blockchain
- 5) Making different blockchains interoperable
- 6) Development of **optimised energy efficient hardware** for blockchain computations





### Blockchain: Use Cases

### <medtech/pharma>

E-PHARMACY
INFRASTRUCTURE

Coupled with IoT, immutable ledge to track drug sourcing, transport conditions (e.g. humidity / temp) and prescription fulfilment (preventing patient abuse of controlled drugs)

Permanent and trusted record unifying information (design plans, risk management, design verification and validation, quality control) that is currently stored across multiple conflicting sources

MEDICAL DEVICE DEVELOPMENT

4

# DATA SHARING FROM WEARABLE DEVICES

Secure digital identities enables patients to retain ownership of health data from medical devices, and revocable authorization of third party access to data

Secure digital identities coupled with IoT enables individual control over health data sharing, enabling home participation in drug trials, or post-drug approval tracking of patient outcomes

DISTRIBUTED DRUG TRIALS DIGITAL REALTIME

# PAYMENTS

<financial services>

Secure digital identities enables universal digital ban accounts, enabling widespread digital realtime payments

Bypasses existing inefficient middleman to significantly reduces fees, allows for near instance remittance and offers traceability in cross border money movements

CROSS BORDER REMITTANCE

INSURANCE UNDERWRITING

Coupled with IoT, provides immutable data for dynamic realtime insurance risk pricing across a wide range of policies (auto, health, climate, crop, livestock)

Allows for near instan settlement, removes need for reconciliation, allows fo continuous markets and provides provenance o trades, and enables liquidity in previously illiquid market

REAL ASSET TOKENIZATION

## <advanced manufacturing>

#### QUALITY CONTROL

Track counterfeit products and assists businesses in making informed decisions with transparency in raw material provenance

Establishing design provenance to deliver printed products that are verified to industry and regulatory standards, while attributing underlying IP to creators

**3D PRINTING** 


PREDICTIVE MAINTENANCE

Provides manufacturers visibility into entire global service supply chain in real time to ensure repairs are made just in time

Allows for secure data sharing amongst the swarm of robots communicating across several channels while maintaining the integrity of informational flow

**SWARM ROBOTICS** 

4



> Covid 19 has exposed and magnified fundamental weaknesses...



### finance



### insurance



...creating multiple human points of failure along entire value chain, including origination, management, and servicing...

3 ...Leading to collapse in bank / insurer ability to service their clients properly, except those that have invested in digital



### healthcare



2 ...whilst patients have largely been **slow to adopt technology** in lieu of physician / hospital visits

Governments and care providers now on a frantic search to provide care, diagnostics, monitoring, and accelerate drug development...

...while patients become aware of their own health, and the potential impact of lifestyle



# industry

Global lockdowns have revealed weak links in global supply chains...

2 ...while multiple layers of complexity obscure manufacturers' ability to have instant online visibility into issues at tier 2 or 3 suppliers

Companies are now incentivized to implement automation solutions to reduce workers on the factory floor, and tighter, realtime situational awareness deeper into supply chains to enable pivots to alternative suppliers if necessary




# agriculture

Border closures hindering the ability of seasonal workforces to travel have severely tightened labour markets in agriculture...


...while demand structurally shifted from the hospitality sector to supermarkets and households

Companies are now incentivized to automate harvests and build agility into supply chains to meet the different ways of reaching the end consumer

> Necessity now drives key stakeholders to "cross the chasm"



> A virtuous cycle of data generation and analytical capabilities



### **DISCLAIMER**

This document is for informational use only, and has not been prepared for, nor should it be considered to be an offer for, the sale or the solicitation of interests or shares in any funds and/or accounts that are managed or advised by Integra Venture Partners Pte. Ltd. or any of its affiliates ("Integra Partners") in any jurisdiction. Any such offer or solicitation may only be made by means of an approved Confidential Private Placement Memorandum of the relevant fund (the "PPM") when available, provided to a potential investor and only in jurisdictions in which such an offering or solicitation would be lawful. In the event of any conflict between this document and the relevant PPM, which will contain a description of the relevant fund's material terms (including risk factors, conflicts of interests, fees and charges, and regulatory and tax considerations), shall prevail.

This document is private and confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published in whole or in part, for any purpose, without the express written permission of Integra Partners. This document is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable laws or regulations. If you (or the legal person you represent) did not receive this document directly from Integra Partners, please return it to Integra Partners at your earliest convenience.

Certain information set forth in this presentation is of a proposed fund which has not been established yet. Information contained herein constitutes and includes, but is not limited to, the focus and expected development of the proposed fund. Although the information is based upon what Integra Partners believes to be reasonable, there can be no assurances that this information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.

The indicative terms and other information included in this document are provided for discussion purposes only and are subject to amendments.

Past results of the relevant fund and/or the respective portfolio companies are not necessarily indicative of future performance and performance may be volatile. No assurance can be given that the relevant fund's investment objective will be achieved. Funds may use substantial amounts of leverage and this may further amplify any losses. Further, investment in a fund is speculative and involves a substantial degree of risk and is therefore only suitable for investors who can afford to lose all or a substantial portion of their investment. Investors should read the PPM carefully, especially the "Risk Factors" section, and the appropriate documents before making a decision to invest in the fund. Unless otherwise stated, references to AUM are inclusive of notional assets and committed capital.

This document has been prepared for the purpose of providing general information only without taking account of any particular investor's objectives, financial situation or needs and does not amount to an investment recommendation. Nothing in this document constitutes accounting, legal, regulatory, financial, tax or other professional advice and is not, and must not be treated as, investment recommendations or investment research. Without prejudice to the generality of the foregoing, nothing herein or in the PPM shall be construed as advice or a recommendation on whether or not to invest in any funds and/or accounts that are managed or advised by Integra Partners has not considered your specific investment objectives, financial situation or particular needs. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate, none of which is offered to you by Integra Partners accepts no duty of care to you in relation to investments. For the avoidance of doubt, Integra Partners does not provide and under no circumstances shall Integra Partners be construed as providing or holding itself out to be providing advice or distributing or promulgating research reports or analyses on the funds and/or accounts that are managed or advised by Integra Partners.

Integra Partners will not act for you (or any other investor) and will not be responsible to you for providing protections afforded to the clients of Integra Partners' investment services. Without prejudice to the generality of the foregoing, Integra Partners does not provide any investment service to you (including, without limitation, the provision of investment advice, or the reception and transmission of orders).

Unless otherwise indicated, the information provided herein is current as of the date herein and has been obtained from sources believed to be reliable. However, Integra Partners makes no representation or warranty, express or implied, regarding the completeness, accuracy or reliability of such information, except as required by law. Such information provided may become quickly outdated, be incomplete, condensed or may be subject to revision. Some of the information contained in this document may contain projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies. These statements are only predictions and actual events or results may differ materially. For the avoidance of doubt, any statements referring to future financial performance of countries, markets, companies or any specific products should not be regarded as any advice or recommendations to buy or sell specific products or make any other investments in relation to the same. Any opinions, estimates, projections or analyses provided to assist the recipient of this document in evaluating the matters described herein may be based on subjective assessments and assumptions which may use various alternative methodologies that produce different results or may not prove to be valid and which may be changed without notice. Accordingly, any projections or analyses should not be relied upon as an accurate prediction of future results.

### **DISCLAIMER**

Integra Partners may issue other materials that are inconsistent with, or reach different conclusions from, the information presented in this document. Those materials may reflect the different assumptions, views, analytical methods and contexts for which those materials were prepared, and Integra Partners is under no obligation to ensure that such other materials are brought to the attention of any recipient of this document.

Integra Partners does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents, or otherwise arising in connection therewith. By accepting receipt of this document, you agree to be bound by the foregoing conditions and limitations and reaffirm your prior consent to the use of your personal data for the purpose of providing for the dispatch of this document and other information on the funds and accounts that are managed or advised by Integra Partners.

The distribution of this document may be further restricted by law. Accordingly, this document may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this document is communicated should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities law.

Reference to individual companies is for the purpose of illustration only and should not be construed as a recommendation to buy or sell the securities of such companies.

Integra Partners holds a capital markets services licence to carry on business in the regulated activity of fund management in respect of the management of portfolios of specified products on behalf of venture capital funds only. "Venture capital fund" has the same meaning as in regulation 14(8) of the Singapore Securities and Futures (Licensing and Conduct of Business) Regulations (Cap. 289, Rg 10). Accordingly, this document and its contents is permitted only for persons who are "institutional investors" or "accredited investors" each within the meaning provided in the Singapore Securities and Futures Act (Cap. 289), or the equivalent class of "accredited investor" under the laws of the country or territory of the person. As an "institutional investor" and/or "accredited investor" certain disclosure requirements under the FAA in relation to the contents of this document or its contents, or otherwise arising in connection therewith. None of the contents in this document have been approved or endorsed by the MAS or any other global regulator.

Notice for persons in Singapore: This document or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of interests or shares in the funds may not be circulated or distributed, nor may the interests or shares in the funds be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than institutional investors (as defined in Section 4A and under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA")), accredited investors (as defined in Section 4A of the SFA) or pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Notice for persons in other jurisdictions: The distribution of this document may be further restricted by law. Accordingly, this document may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this document is communicated should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities law.

© 2020 Integra Partners. All Rights Reserved.